Regenicin, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021
May 17, 2021 at 03:46 pm EDT
Share
Regenicin, Inc. announced earnings results for the second quarter ended March 31, 2021. For the second quarter, the company announced operating loss was USD 225,736 compared to USD 162,858 a year ago. Net loss was USD 233,304 compared to USD 188,648 a year ago. For the half year, operating loss was USD 376,554 compared to USD 355,208 a year ago. Net loss was USD 393,182 compared to USD 386,634 a year ago.
Regenicin, Inc. is a biotechnology company that is focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. It is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas in patients, such as ulcers. Its application is used for the treatment of chronic skin wounds.
REGENICIN, INC. 
